Scientists test new DNA-Based shot in quest for HIV vaccine
NCT ID NCT05828095
Summary
This early-stage study tested the safety and immune response of a new experimental HIV vaccine in healthy adults. Twenty participants received either the new DNA-based vaccine alone or in combination with another vaccine shot. The main goal was to see if the vaccines were safe and if they could trigger the body to produce antibodies and immune cells that target HIV.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
New York Blood Center CRS
New York, New York, 10065, United States
-
Penn Prevention CRS
Philadelphia, Pennsylvania, 19104, United States
-
Vanderbuilt Vaccine (VV) CRS
Nashville, Tennessee, 37232, United States
Conditions
Explore the condition pages connected to this study.